- Open Access
The emerging role of hepatitis B virus Pre-S2 deletion mutant proteins in HBV tumorigenesis
© Su et al.; licensee BioMed Central Ltd. 2014
- Received: 28 April 2014
- Accepted: 7 October 2014
- Published: 15 October 2014
Chronic hepatitis B virus (HBV) infection can cause hepatocellular carcinoma (HCC). Several hypotheses have been proposed to explain the mechanisms of HBV tumorigenesis, including inflammation and liver regeneration associated with cytotoxic immune injuries and transcriptional activators of mutant HBV gene products. The mutant viral oncoprotein-driven tumorigenesis is prevailed at the advanced stage or anti-HBe-positive phase of chronic HBV infection. Besides HBx, the pre-S2 (deletion) mutant protein represents a newly recognized oncoprotein that is accumulated in the endoplasmic reticulum (ER) and manifests as type II ground glass hepatocytes (GGH). The retention of pre-S2 mutant protein in ER can induce ER stress and initiate an ER stress-dependent VEGF/Akt/mTOR and NFκB/COX-2 signal pathway. Additionally, the pre-S2 mutant large surface protein can induce an ER stress-independent pathway to transactivate JAB-1/p27/RB/cyclin A,D pathway, leading to growth advantage of type II GGH. The pre-S2 mutant protein-induced ER stress can also cause DNA damage, centrosome overduplication, and genomic instability. In 5-10% of type II GGHs, there is co-expression of pre-S2 mutant protein and HBx antigen which exhibited enhanced oncogenic effects in transgenic mice. The mTOR signal cascade is consistently activated throughout the course of pre-S2 mutant transgenic livers and in human HCC tissues, leading to metabolic disorders and HCC tumorigenesis. Clinically, the presence of pre-S2 deletion mutants in sera frequently develop resistance to nucleoside analogues anti-virals and predict HCC development. The pre-S2 deletion mutants and type II GGHs therefore represent novel biomarkers of HBV-related HCCs. A versatile DNA array chip has been developed to detect pre-S2 mutants in serum. Overall, the presence of pre-S2 mutants in serum has implications for anti-viral treatment and can predict HCC development. Targeting at pre-S2 mutant protein-induced, ER stress-dependent, mTOR signal cascade and metabolic disorders may offer potential strategy for chemoprevention or therapy in high risk chronic HBV carriers.
- Ground glass hepatocytes
- Pre-S mutants
- Endoplasmic reticulum stress
- Chronic HBV infection
- Hepatocellular carcinoma
Hepatitis B virus ( HBV ) has been well established to cause hepatocellular carcinoma ( HCCs ) . Several hypotheses have been proposed to explain the mechanism of HBV tumorigenesis, including inflammation and liver regeneration associated with cytotoxic immune injuries, HBV DNA insertional mutagenesis, and viral oncoproteins-driven tumorigenesis -. Although HCC can occur at any stage of chronic HBV infection, the majority of cases occur at the advanced stage or anti-HBe-positive phase with the peak incidence at sixth decade . The development of HCC related to the inflammation and liver regeneration is likely due to the cytotoxic T cell immune injuries toward HBV antigen-expressing hepatocytes which may result in bridging hepatic necrosis and fibrosis ,. In the anti-HBe-positive phase, however, the mutant viral oncoproteins may play an important or driving role in HCC development.
The above-mentioned observation of the unique biologic and pathologic features of type II GGHs drives us to explore in details the underlying molecular and biologic mechanism of type II GGHs and its potential significance in HBV tumorigenesis. In the past decade, we clarified the biologic and molecular significance of type II GGHs which contain a unique form of pre-S2 deletion mutant large surface protein (pre-S2 mutant). The significance of pre-S2 mutant proteins in HCC development, the signal pathway initiated by pre-S2 mutant proteins, and the transgenic mice model of pre-S2 mutant tumorigenesis were studied in detail. Importantly, we developed a DNA array chip to detect pre-S2 mutant gene as the predictive marker of HCC in chronic HBV carriers. Potential chemoprevention or therapy targeting at mTOR signal cascade and metabolic pathway was proposed in this review.
Ground glass hepatocytes contain pre-S deletion mutant proteins which accumulate in endoplasmic reticulum (ER) and induce ER stress signals
By dissecting the cirrhotic nodules containing type II GGHs, we are surprised to find that type II GGHs consistently harbored pre-S2 mutants with in-frame deletions over the pre-S2 regions (predominantly, nt. 2-55 or 4-57) with or without point mutations at the start codon (ATG-ATA) of the middle surface gene in the pre-S2 region. These mutations lead to a decreased synthesis of middle and small surface antigens and result in a defective secretion of the mutant large surface antigens which then accumulate in ER, leading to the GGH formation in chronic HBV infection ,. It is also interesting to note that the deletion site at the pre-S2 region coincides with the epitope of cytotoxic T-cell and B-cell neutralization responses and suggests that the pre-S2 deletion mutants represent an immune escape mutant ,, This hypothesis is supported by the pathologic observation that the hepatic lobules, which contain type II GGH, usually show no inflammatory activities or lymphocyte infiltration ,,. Distinct from type II GGHs, the singly distributed type I GGHs contain entirely different pre-S mutants with variable deletions over the pre-S1 regions. The deletion sites at the pre-S1 region may interfere with the transcriptional activities of the pre-S2/S promoter and affect the regulation of HBV replication and synthesis of small surface antigens ,. The pre-S1 containing large surface antigen (LHB) exhibits a dual topology, and only half of the LHB translocate post-translationally into the ER lumen ,. The pre-S regions that remain in cytoplasmic orientation can bind to the cytosolic heat shock protein Hsc70  and presumably interact with the core particle during virion assembly . The cytoplasmic orientation of the pre-S region is required for the transcriptional activator function of LHB and middle surface protein in vitro ,. The luminal orientation of the pre-S domain, after virus maturation and secretion, is exposed on the surface of the virion and is involved in virus attachment and recognition ,. Mutants with various types of in-frame deletion in pre-S1 region were found to be replication competent in vitro ,, and can be the predominant strain in vivo -. In HCC patients, the pre-S mutants are prevalent for up to 63%, including mutants with combinations of deletions over the pre-S1 and pre-S2 regions (Figure 1B) ,.
The accumulation of mutant or unfolded proteins causes stress in ER that is sensed by the glucose-regulated protein 78 (Grp78). Unfolded proteins will sequester GRP78 and dissociate from three ER transmembrane transducers leading to their activation . The activation of ER stress has been implicated in a variety of human diseases including neurodegenerative disease, inflammation, and cancer . It has been demonstrated that the secretion of surface proteins was compromised by pre-S deletions, especially pre-S2 mutants . In addition, ectopic expression of pre-S mutant proteins in Huh-7 cells increased the levels of ER chaperones (Grp78 and 94) and activated PERK and C-jun N-terminal kinase (JNK) . These results indicate that both pre-S1 and pre-S2 mutant surface proteins induce ER stress signals in hepatocytes. In consistence with this assumption, elevated Grp78 expression was detected in both type I and type II GGHs in the liver . Northern and Western blot analyses revealed that the pre-S1 mutant induced stronger levels of ER chaperone (Grp78 and 94) response, calcium release, cyclooxygenase-2 (COX-2) and inflammatory cytokines, and oxidative stress intermediates, which tend to result in apoptosis ,,. The pre-S2 mutants, albeit inducing a weaker level of ER stress signal, exhibited higher levels of mutation frequency and transforming capabilities in primary hepatocyte cell line HH4 .
One remarkable biological phenomenon conferred by pre-S1 and pre-S2 mutant proteins is the distinct subcellular localizations of these two proteins in the hepatocytes. Accumulation of pre-S1 mutant proteins frequently displayed an inclusion-like configuration in type I GGHs (Figure 1). In contrast, peripheral or marginal distribution of pre-S2 mutant proteins was evident in type II GGHs ,. It is plausible that marginal distribution of pre-S2 mutant proteins is a result of an active recruitment process of pre-S2 mutant proteins, by other ER components, towards the cell periphery. The triggering factor of this recruitment and the patho-biological implication of this process will shed light on the pathogenesis of GGHs as the pre-neoplastic lesions for the development of HCC.
ER stress-dependent and-independent pathways induced by pre-S2 mutants, leading to oxidative DNA damage, genomic instability, and transforming capabilities in transgenic mice model
The most important molecular mechanism initiated by pre-S2 mutant is the VEGF/Akt/mTOR signal pathway which is activated in Huh-7 cells and sequentially activated at the early, middle, and advanced stages of transgenic livers harboring pre-S2 deletion mutant (Figure 2) ,. The mTOR signaling is commonly activated in human HCC tissues and represents a candidate target for therapy. The transforming ability of pre-S2 mutant proteins has been investigated in an immortalized human hepatocyte line HH4 . In addition, transgenic mice carrying pre-S2 mutant developed HCC . These studies further support the role of pre-S2 mutants and GGHs in HBV hepatocarcinogenesis ,.
Aside from the ER stress-dependent signaling pathways, a distinct ER stress-independent response has been found specifically for pre-S2 deletion mutant protein and is significant for their biologic and carcinogenic preferences . The pre-S2 mutant protein specifically interacts with c-Jun activation domain binding protein 1 (JAB1), which enhances activator protein-1 transcriptional activity and cell proliferation . Through its binding to JAB1, the pre-S2 mutant protein induces JAB1 nuclear translocation, which activates p27/retinoblastoma/Cdk2/cyclin A, D pathways and leads to cell cycle progression and centrosome over-duplication ,. These findings have provided clear mechanisms for the growth advantage induced by the pre-S2 mutant protein.
Two HBV viral proteins, the X protein (HBx) and pre-S2 deletion mutant protein, have been considered to have either direct or indirect effects in HBV hepatocarcinogenesis . Other than the molecular mechanisms of pre-S2 deletion mutants in hepatocarcinogenesis as mentioned above, HBx also has been shown to mediate the activation of multiple signal pathways including the mTOR signal cascade -. In our laboratory, we observed a strong HBx expression in the cytosolic fraction of GGHs in 5 of 20 HBsAg-positive human livers. Interestingly, HBx was consistently co-expressed with HBsAg, but not vice versa, in GGHs. The expression of both oncoproteins, however, was only rarely detected in HCC tissues . Transgenic mice harboring the HBx, pre-S2 mutant, and a double (HBx plus pre-S2 mutant) construct have been established in our laboratory. We observed that the transgenic livers harboring double construct plasmids developed HCCs at an average of 15.1 months, earlier than that of HBx (16.9 months) or pre-S2 mutant (24.5 months) alone. Interestingly, the oncogenic signals of VEGF-A, p-Akt1/2/3, mitogen-activated protein kinases ( MAPK) signaling, and p-mTOR were sequentially and differentially activated at different stages in the progression of tumorigenesis . The combined expression of HBx and pre-S2 mutant can exhibit enhanced oncogenic effects in HBV tumorigenesis. The exact role of HBx and pre-S2 mutant protein, either alone or in combination, in human HCC development remains to be clarified.
Presence of pre-S2 mutants in serum predicts the resistance of nucleoside analogues anti-virals and a higher risk of HCC development
The emergence of pre-S deletion mutants occurs during the natural course of HBV infection, possibly due to selective pressure by the immune system ,. The frequencies of pre-S mutation increased successively in different stage of chronic HBV infection. In a meta-analysis study , the summarized results showed that pre-S mutants were detected in around 10% of asymptomatic HBsAg carriers, 20% of patients with chronic hepatitis B, 35% of patients with liver cirrhosis and 50% patients with HCC. The pre-S2 deletion mutants are more frequently detected in anti-HBeAg-positive patients and in patients with HCC than in HBeAg-positive patients ,,. The ratio of pre-S mutant clones related to wild type in serum also accumulates, as it was 6.4% at high replicative phase, 13% at intermediate, and 37.5% at low or nonreplicative phases . Therefore, pre-S2 mutants represent a significant proportion of virus in advanced stage patients ,.
Although anti-viral nucleoside analogues therapy has been associated with a lower risk of HCC development or recurrence after liver resection in chronic HBV carriers , the frequencies of pre-S mutants have been reported to be increased after antiviral therapy by nucleos(t)ide analogues which is closely associated with the drug resistance and predict the high risk development of HCC ,. Interestingly, in the control group treated with alpha-interferon, the pre-S2 mutants were significantly reduced or absent, suggesting that alpha-interferon may degrade or inhibit the synthesis of pre-S2 mutant proteins . The presence of pre-S mutants, especially pre-S2 mutant, has been found to be significantly associated with the risk of HCC development -. Pre-S deletion mutants detected in serum has also been reported to increase the risk of post-operative recurrence of HCC . Of particular note, pre-S mutation could occur early in age and significantly associated with HCC in pediatric patients ,. Pre-S2 deletion mutants in sera can be detected in nearly half of children with HCC, in contrast to none in children with chronic HBV infection . By using tissue samples, pre-S2 deletion mutants can be detected in about 80% of pediatric HCC . Overall, the combined effects of cell cycle progression, genomic instabilities, and survival advantage exhibited by pre-S2 mutant proteins strongly suggest that type II GGHs are potential preneoplastic loci for HCC development and de novo recurrence after surgical resection. In a cohort of 82 patients with HBV-related HCC who received curative surgery , type II GGHs were found to be the independent variables associated with late recurrence and the overall survival. However, a prospective cohort study is needed to test the specificity and sensitivity of pre-S2 deletion mutants and ground glass hepatocytes in the predictive value of HCCs.
Development of DNA chip to detect pre-S2 mutants in serum as the predictive hallmark of HCC
To efficiently detect pre-S deletion mutants in serum, we have successfully developed the oligonucleotide Pre-S Gene Chip to detect the pre-S deletion mutants in sera. The Pre-S Gene Chip contains 42 DNA probes that target the pre-S region of the LHBS gene, offering a highly sensitive and specific method for pre-S deletion detection with short turnaround time (≤3 days) . Screening the pre-S deletion mutants revealed interesting findings that the detection rate of pre-S mutants were relatively low (7%) in the sera of patients with acute exacerbation of chronic HBV infection but gradually increased in later periods of chronic HBV infection, as they were 37% in advanced stage of chronic HBV carriers, and as high as 60% in HCC patients . Combined detection of pre-S mutants and other markers of HBV replication such as HBeAg and viral loads is believed to offer a reliable predictive method for predicting HCC risks in chronic HBV carriers.
Potential chemoprevention or therapy of HBV-related HCCs targeting at ER stress-induced signal cascade and metabolic disorders
In this review, we provide a comprehensive overview to provide evidence on the emerging role of HBV pre-S2 deletion mutant protein in HBV tumorigenesis. The HBV pre-S2 deletion mutant proteins are retained in the ER and induce ER stress response. Series of ER stress-dependent and -independent growth signals are then activated. Among the diverse pathways, mTOR-mediated signal cascade represent a major mechanism for the disturbed metabolism, genomic instability, and growth advantage, which drive the type II GGHs toward the pre-neoplastic and neoplastic lesions. To identify the patients at high risk for HCC development represents the major task in combating chronic HBV infection in the coming decades. The development of a DNA chip for detecting pre-S2 deletion mutant will meet this demand. Chemopreventive or therapeutic agents can then be provided to these high risk HBV carriers to prevent from HCC development.
This study was supported by grants from National Health Research Institutes and National Science Council, Taiwan (Dr. Su and Dr. Huang).
- Beasley RP, Hwang LY, Lin CC, Chien CS: Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981, 2: 1129-1133. 10.1016/S0140-6736(81)90585-7.View ArticlePubMedGoogle Scholar
- Su IJ, Hsieh WC, Tsai HW, Wu HC: Chemoprevention and novel therapy for hepatocellular carcinoma associated with chronic hepatitis B virus infection. Hepatobiliary Surg Nutr. 2013, 2: 37-39.PubMed CentralPubMedGoogle Scholar
- Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, Esposito A, Ruggeri ZM, Chisari FV, Iannacone M, Guidotti LG: Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A. 2012, 109: E2165-E2172. 10.1073/pnas.1209182109.PubMed CentralView ArticlePubMedGoogle Scholar
- Liaw YF, Chu CM: Hepatitis B virus infection. Lancet. 2009, 373: 582-592. 10.1016/S0140-6736(09)60207-5.View ArticlePubMedGoogle Scholar
- Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL, Palmiter RD: Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell. 1989, 59: 1145-1156. 10.1016/0092-8674(89)90770-8.View ArticlePubMedGoogle Scholar
- Hadziyannis S, Gerber MA, Vissoulis C, Popper H: Cytoplasmic hepatitis B antigen in "ground-glass" hepatocytes of carriers. Arch Pathol. 1973, 96: 327-330.PubMedGoogle Scholar
- Popper H: The ground glass hepatocyte as a diagnostic hint. Hum Pathol. 1975, 6: 517-520. 10.1016/S0046-8177(75)80069-4.View ArticlePubMedGoogle Scholar
- Shikata T: Australia antigen in liver tissue-an immunofluorescent and immunoelectron microscopic study. Jpn J Exp Med. 1973, 43: 231-245.PubMedGoogle Scholar
- Gudat F, Bianchi L, Sonnabend W, Thiel G, Aenishaenslin W, Stalder GA: Pattern of core and surface expression in liver tissue reflects state of specific immune response in hepatitis B. Lab Invest. 1975, 32: 1-9.PubMedGoogle Scholar
- Hsu HC, Lai MY, Su IJ, Chen DS, Chang MH, Yang PM, Wu CY, Hsieh HC: Correlation of hepatocyte HBsAg expression with virus replication and liver pathology. Hepatology. 1988, 8: 749-754. 10.1002/hep.1840080408.View ArticlePubMedGoogle Scholar
- Wang HC, Wu HC, Chen CF, Fausto N, Lei HY, Su IJ: Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol. 2003, 163: 2441-2449. 10.1016/S0002-9440(10)63599-7.PubMed CentralView ArticlePubMedGoogle Scholar
- Su IJ, Kuo TT, Liaw YF: Hepatocyte hepatitis B surface antigen. Diagnostic evaluation of patients with clinically acute hepatitis B surface antigen-positive hepatitis. Arch Pathol Lab Med. 1985, 109: 400-402.PubMedGoogle Scholar
- Hsu HC, Lin YH, Chang MH, Su IJ, Chen DS: Pathology of chronic hepatitis B virus infection in children: with special reference to the intrahepatic expression of hepatitis B virus antigens. Hepatology. 1988, 8: 378-382. 10.1002/hep.1840080232.View ArticlePubMedGoogle Scholar
- Su IJ, Lai MY, Hsu HC, Chen DS, Yang PM, Chuang SM, Sung JL: Diverse virological, histopathological and prognostic implications of seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. J Hepatol. 1986, 3: 182-189. 10.1016/S0168-8278(86)80024-1.View ArticlePubMedGoogle Scholar
- Fan YF, Lu CC, Chang YC, Chang TT, Lin PW, Lei HY, Su IJ: Identification of a pre-S2 mutant in hepatocytes expressing a novel marginal pattern of surface antigen in advanced diseases of chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2000, 15: 519-528. 10.1046/j.1440-1746.2000.02187.x.View ArticlePubMedGoogle Scholar
- Tai PC, Banik D, Lin GI, Pai S, Pai K, Lin MH, Yuoh G, Che S, Hsu SH, Chen TC, Kuo TT, Lee CS, Yang CS, Shih C: Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J Virol. 1997, 71: 4852-4856.PubMed CentralPubMedGoogle Scholar
- Tai PC, Suk FM, Gerlich WH, Neurath AR, Shih C: Hypermodification and immune escape of an internally deleted middle-envelope (M) protein of frequent and predominant hepatitis B virus variants. Virology. 2002, 292: 44-58. 10.1006/viro.2001.1239.View ArticlePubMedGoogle Scholar
- Hsu HC, Wu TT, Wu MZ, Wu CY, Chiou TJ, Sheu JC, Lee CS, Chen DS: Evolution of expression of hepatitis B surface and core antigens (HBsAg, HBcAg) in resected primary and recurrent hepatocellular carcinoma in HBsAg carriers in Taiwan. Correlation with local host immune response. Cancer. 1988, 62: 915-921. 10.1002/1097-0142(19880901)62:5<915::AID-CNCR2820620511>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
- Melegari M, Scaglioni PP, Wands JR: The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deleted. J Virol. 1997, 71: 5449-5454.PubMed CentralPubMedGoogle Scholar
- Xu Z, Yen TS: Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. J Virol. 1996, 70: 133-140.PubMed CentralPubMedGoogle Scholar
- Bruss V, Lu X, Thomssen R, Gerlich WH: Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. EMBO J. 1994, 13: 2273-2279.PubMed CentralPubMedGoogle Scholar
- Ostapchuk P, Hearing P, Ganem D: A dramatic shift in the transmembrane topology of a viral envelope glycoprotein accompanies hepatitis B viral morphogenesis. EMBO J. 1994, 13: 1048-1057.PubMed CentralPubMedGoogle Scholar
- Loffler-Mary H, Werr M, Prange R: Sequence-specific repression of cotranslational translocation of the hepatitis B virus envelope proteins coincides with binding of heat shock protein Hsc70. Virology. 1997, 235: 144-152. 10.1006/viro.1997.8689.View ArticlePubMedGoogle Scholar
- Le Pogam S, Shih C: Influence of a putative intermolecular interaction between core and the pre-S1 domain of the large envelope protein on hepatitis B virus secretion. J Virol. 2002, 76: 6510-6517. 10.1128/JVI.76.13.6510-6517.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Hildt E, Hofschneider PH: The PreS2 activators of the hepatitis B virus: activators of tumour promoter pathways. Recent Results Cancer Res. 1998, 154: 315-329. 10.1007/978-3-642-46870-4_23.View ArticlePubMedGoogle Scholar
- Hildt E, Urban S, Eckerskorn C, Hofschneider PH: Isolation of highly purified, functional carboxy-terminally truncated hepatitis B virus middle surface protein activators from eucaryotic expression systems. Hepatology. 1996, 24: 502-507. 10.1002/hep.510240306.View ArticlePubMedGoogle Scholar
- Klingmuller U, Schaller H: Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. J Virol. 1993, 67: 7414-7422.PubMed CentralPubMedGoogle Scholar
- Neurath AR, Kent SB, Strick N, Parker K: Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell. 1986, 46: 429-436. 10.1016/0092-8674(86)90663-X.View ArticlePubMedGoogle Scholar
- Melegari M, Bruno S, Wands JR: Properties of hepatitis B virus pre-S1 deletion mutants. Virology. 1994, 199: 292-300. 10.1006/viro.1994.1127.View ArticlePubMedGoogle Scholar
- Bock CT, Tillmann HL, Maschek HJ, Manns MP, Trautwein C: A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology. 1997, 113: 1976-1982. 10.1016/S0016-5085(97)70018-0.View ArticlePubMedGoogle Scholar
- Pult I, Chouard T, Wieland S, Klemenz R, Yaniv M, Blum HE: A hepatitis B virus mutant with a new hepatocyte nuclear factor 1 binding site emerging in transplant-transmitted fulminant hepatitis B. Hepatology. 1997, 25: 1507-1515. 10.1002/hep.510250633.View ArticlePubMedGoogle Scholar
- Santantonio T, Jung MC, Schneider R, Fernholz D, Milella M, Monno L, Pastore G, Pape GR, Will H: Hepatitis B virus genomes that cannot synthesize pre-S2 proteins occur frequently and as dominant virus populations in chronic carriers in Italy. Virology. 1992, 188: 948-952. 10.1016/0042-6822(92)90559-8.View ArticlePubMedGoogle Scholar
- Su IJ, Wang HC, Wu HC, Huang WY: Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2008, 23: 1169-1174. 10.1111/j.1440-1746.2008.05348.x.View ArticlePubMedGoogle Scholar
- Fan YF, Lu CC, Chen WC, Yao WJ, Wang HC, Chang TT, Lei HY, Shiau AL, Su IJ: Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology. 2001, 33: 277-286. 10.1053/jhep.2001.21163.View ArticlePubMedGoogle Scholar
- Malhi H, Kaufman RJ: Endoplasmic reticulum stress in liver disease. J Hepatol. 2011, 54: 795-809. 10.1016/j.jhep.2010.11.005.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang S, Kaufman RJ: The impact of the unfolded protein response on human disease. J Cell Biol. 2012, 197: 857-867. 10.1083/jcb.201110131.PubMed CentralView ArticlePubMedGoogle Scholar
- Hung JH, Su IJ, Lei HY, Wang HC, Lin WC, Chang WT, Huang W, Chang WC, Chang YS, Chen CC, Lai MD: Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp 38 mitogen-activated protein kinase. J Biol Chem. 2004, 279: 46384-46392. 10.1074/jbc.M403568200.View ArticlePubMedGoogle Scholar
- Hsieh YH, Su IJ, Wang HC, Chang WW, Lei HY, Lai MD, Chang WT, Huang W: Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis. 2004, 25: 2023-2032. 10.1093/carcin/bgh207.View ArticlePubMedGoogle Scholar
- Wang HC, Chang WT, Chang WW, Wu HC, Huang W, Lei HY, Lai MD, Fausto N, Su IJ: Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology. 2005, 41: 761-770. 10.1002/hep.20615.View ArticlePubMedGoogle Scholar
- Wang HC, Huang W, Lai MD, Su IJ: Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci. 2006, 97: 683-688. 10.1111/j.1349-7006.2006.00235.x.View ArticlePubMedGoogle Scholar
- Malhotra JD, Miao H, Zhang K, Wolfson A, Pennathur S, Pipe SW, Kaufman RJ: Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc Natl Acad Sci U S A. 2008, 105: 18525-18530. 10.1073/pnas.0809677105.PubMed CentralView ArticlePubMedGoogle Scholar
- Hsieh YH, Hsu JL, Su IJ, Huang W: Genomic instability caused by hepatitis B virus: into the hepatoma inferno. Front Biosci (Landmark Ed). 2011, 16: 2586-2597. 10.2741/3874.View ArticleGoogle Scholar
- Wang LH, Huang W, Lai MD, Su IJ: Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis. Carcinogenesis. 2012, 33: 466-472. 10.1093/carcin/bgr296.View ArticlePubMedGoogle Scholar
- Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF, Hsu YH, Huang W, Wu LW, Su IJ: Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology. 2009, 49: 1962-1971. 10.1002/hep.22889.View ArticlePubMedGoogle Scholar
- Wu HC, Tsai HW, Teng CF, Hsieh WC, Lin YJ, Wang LHC, Yuan Q, Su IJ: Ground-glass hepatocytes co-expressing hepatitis B virus X protein and surface antigens exhibit enhanced oncogenic effects and tumorigenesis. Hum Pathol. 2014, 45: 1294-1301. 10.1016/j.humpath.2013.10.039.View ArticlePubMedGoogle Scholar
- Mathai AM, Alexander J, Kuo FY, Torbenson M, Swanson PE, Yeh MM: Type II ground-glass hepatocytes as a marker of hepatocellular carcinoma in chronic hepatitis B. Hum Pathol. 2013, 44: 1665-1671. 10.1016/j.humpath.2013.01.020.View ArticlePubMedGoogle Scholar
- Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ: Viral hepatocarcinogenesis: from infection to cancer. Liver Int. 2008, 28: 175-188. 10.1111/j.1478-3231.2007.01652.x.View ArticlePubMedGoogle Scholar
- Benn J, Schneider RJ: Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A. 1994, 91: 10350-10354. 10.1073/pnas.91.22.10350.PubMed CentralView ArticlePubMedGoogle Scholar
- Chan CF, Yau TO, Jin DY, Wong CM, Fan ST, Ng IO: Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res. 2004, 10: 4140-4149. 10.1158/1078-0432.CCR-03-0574.View ArticlePubMedGoogle Scholar
- Lee YI, Kang-Park S, Do SI, Lee YI: The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem. 2001, 276: 16969-16977. 10.1074/jbc.M011263200.View ArticlePubMedGoogle Scholar
- Lee YH, Yun Y: HBx protein of hepatitis B virus activates Jak1-STAT signaling. J Biol Chem. 1998, 273: 25510-25515. 10.1074/jbc.273.39.25510.View ArticlePubMedGoogle Scholar
- Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF, Chang KY, Huang WC, Lin PW, Chiang CW, Chang TT: Hepatitis B virus X protein upregulates mTOR signaling through IKKbeta to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One. 2012, 7: e41931-10.1371/journal.pone.0041931.PubMed CentralView ArticlePubMedGoogle Scholar
- Mimms L: Hepatitis B virus escape mutants: "pushing the envelope" of chronic hepatitis B virus infection. Hepatology. 1995, 21: 884-887.PubMedGoogle Scholar
- Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G: Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst. 2009, 101: 1066-1082. 10.1093/jnci/djp180.PubMed CentralView ArticlePubMedGoogle Scholar
- Huy TT, Ushijima H, Win KM, Luengrojanakul P, Shrestha PK, Zhong ZH, Smirnov AV, Taltavull TC, Sata T, Abe K: High prevalence of hepatitis B virus pre-s mutant in countries where it is endemic and its relationship with genotype and chronicity. J Clin Microbiol. 2003, 41: 5449-5455. 10.1128/JCM.41.12.5449-5455.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H: Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology. 1993, 194: 137-148. 10.1006/viro.1993.1243.View ArticlePubMedGoogle Scholar
- Le Seyec J, Chouteau P, Cannie I, Guguen-Guillouzo C, Gripon P: Role of the pre-S2 domain of the large envelope protein in hepatitis B virus assembly and infectivity. J Virol. 1998, 72: 5573-5578.PubMed CentralPubMedGoogle Scholar
- Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT: Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012, 308: 1906-1914. 10.1001/2012.jama.11975.View ArticlePubMedGoogle Scholar
- Zhang D, Dong P, Zhang K, Deng L, Bach C, Chen W, Li F, Protzer U, Ding H, Zeng C: Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment. BMC Microbiol. 2012, 12: 307-10.1186/1471-2180-12-307.PubMed CentralView ArticlePubMedGoogle Scholar
- Pollicino T, Cacciola I, Saffioti F, Raimondo G: Hepatitis B virus PreS/S gene variants: Pathobiology and clinical implications. J Hepatol. 2014, 61: 408-417. 10.1016/j.jhep.2014.04.041.View ArticlePubMedGoogle Scholar
- Kao JH, Liu CJ, Jow GM, Chen PJ, Chen DS, Chen BF: Fine mapping of hepatitis B virus pre-S deletion and its association with hepatocellular carcinoma. Liver Int. 2012, 32: 1373-1381. 10.1111/j.1478-3231.2012.02826.x.View ArticlePubMedGoogle Scholar
- Fang ZL, Sabin CA, Dong BQ, Wei SC, Chen QY, Fang KX, Yang JY, Huang J, Wang XY, Harrison TJ: Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study. J Gen Virol. 2008, 89: 2882-2890. 10.1099/vir.0.2008/002824-0.PubMed CentralView ArticlePubMedGoogle Scholar
- Sinn DH, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Yoo BC: Pre-s mutation is a significant risk factor for hepatocellular carcinoma development: a long-term retrospective cohort study. Dig Dis Sci. 2013, 58: 751-758. 10.1007/s10620-012-2408-9.View ArticlePubMedGoogle Scholar
- Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, Lu SN, Changchien CS: Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology. 2007, 133: 1466-1474. 10.1053/j.gastro.2007.09.002.View ArticlePubMedGoogle Scholar
- Su CW, Chiou YW, Tsai YH, Teng RD, Chau GY, Lei HJ, Hung HH, Huo TI, Wu JC: The influence of hepatitis B viral load and pre-S deletion mutations on post-operative recurrence of hepatocellular carcinoma and the tertiary preventive effects by anti-viral therapy. PLoS One. 2013, 8: e66457-10.1371/journal.pone.0066457.PubMed CentralView ArticlePubMedGoogle Scholar
- Huang HP, Hsu HY, Chen CL, Ni YH, Wang HY, Tsuei DJ, Chiang CL, Tsai YC, Chen HL, Chang MH: Pre-S2 deletions of hepatitis B virus and hepatocellular carcinoma in children. Pediatr Res. 2010, 67: 90-94. 10.1203/PDR.0b013e3181c1b0b7.View ArticlePubMedGoogle Scholar
- Abe K, Thung SN, Wu HC, Tran TT, Le Hoang P, Truong KD, Inui A, Jang JJ, Su IJ: Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci. 2009, 100: 2249-2254. 10.1111/j.1349-7006.2009.01309.x.View ArticlePubMedGoogle Scholar
- Tsai HW, Lin YJ, Lin PW, Wu HC, Hsu KH, Yen CJ, Chan SH, Huang W, Su IJ: A clustered ground-glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery. Cancer. 2011, 117: 2951-2960. 10.1002/cncr.25837.View ArticlePubMedGoogle Scholar
- Shen FC, Su IJ, Wu HC, Hsieh YH, Yao WJ, Young KC, Chang TC, Hsieh HC, Tsai HN, Huang W: A pre-S gene chip to detect pre-S deletions in hepatitis B virus large surface antigen as a predictive marker for hepatoma risk in chronic hepatitis B virus carriers. J Biomed Sci. 2009, 16: 84-10.1186/1423-0127-16-84.PubMed CentralView ArticlePubMedGoogle Scholar
- Cornu M, Albert V, Hall MN: mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev. 2013, 23: 53-62. 10.1016/j.gde.2012.12.005.View ArticlePubMedGoogle Scholar
- Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, Cursaro C, Danila M, de Sio I, Floreani A, Freni MA, Grieco A, Groppo M, Lazzari R, Lobello S, Lorefice E, Margotti M, Miele L, Milani S, Okolicsanyi L, Palasciano G, Portincasa P, Saltarelli P, Smedile A, Somalvico F, Spadaro A, Sporea I, Sorrentino P, Vecchione R, Tuccillo C: Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med. 2012, 52: 1658-1665. 10.1016/j.freeradbiomed.2012.02.008.View ArticlePubMedGoogle Scholar
- Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH: Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A. 2010, 107: 5995-5999. 10.1073/pnas.0914009107.PubMed CentralView ArticlePubMedGoogle Scholar
- Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997, 275: 218-220. 10.1126/science.275.5297.218.View ArticlePubMedGoogle Scholar
- Gusman J, Malonne H, Atassi G: A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis. 2001, 22: 1111-1117. 10.1093/carcin/22.8.1111.View ArticlePubMedGoogle Scholar
- Fulda S: Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today. 2010, 15: 757-765. 10.1016/j.drudis.2010.07.005.View ArticlePubMedGoogle Scholar
- Guarente L: Sirtuins as potential targets for metabolic syndrome. Nature. 2006, 444: 868-874. 10.1038/nature05486.View ArticlePubMedGoogle Scholar
- Lekli I, Ray D, Das DK: Longevity nutrients resveratrol, wines and grapes. Genes Nutr. 2010, 5: 55-60. 10.1007/s12263-009-0145-2.PubMed CentralView ArticlePubMedGoogle Scholar
- Hsieh WC, Yang CW, Haung YS, Chao TW, Tsai TF, Su IJ: Chemoprevention of HBV-related hepatocellular carcinoma by the combined product of resveratrol and silymarin in transgenic mice. Funct Foods Health Dis. 2013, 3: 341-352.Google Scholar
This article is published under license to BioMed Central Ltd.